Page last updated: 2024-09-03
elacridar and st 1481
elacridar has been researched along with st 1481 in 1 studies
Compound Research Comparison
| Studies (elacridar) | Trials (elacridar) | Recent Studies (post-2010) (elacridar) | Studies (st 1481) | Trials (st 1481) | Recent Studies (post-2010) (st 1481) |
|---|---|---|---|---|---|
| 284 | 8 | 119 | 49 | 5 | 15 |
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Beijnen, JH; Iusuf, D; Lin, F; Marchetti, S; Mazzanti, R; Pluim, D; Schellens, JH; van Tellingen, O | 1 |
Other Studies
1 other study(ies) available for elacridar and st 1481
| Article | Year |
|---|---|
Abcc4 together with abcb1 and abcg2 form a robust cooperative drug efflux system that restricts the brain entry of camptothecin analogues.
Topics: Acridines; Administration, Intravenous; Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blood-Brain Barrier; Brain; Camptothecin; Chromatography, High Pressure Liquid; Irinotecan; Mice; Mice, Knockout; Multidrug Resistance-Associated Proteins; Tetrahydroisoquinolines; Topotecan | 2013 |